Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis
2011-000362-35Phase 2Completed
- Sponsor
- Bioinova
- Start
- Apr 2011
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human autologous mesenchymal stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Bioinova. Primary endpoint: Complication at the site of intrathecal infusion. Started Apr 2011; status: completed.
02
Drugs
human autologous mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2011-000362-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000362-35.